Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated.
Maas SLN, Stichel D, Hielscher T, Sievers P, Berghoff AS, Schrimpf D, Sill M, Euskirchen P, Blume C, Patel A, Dogan H, Reuss D, Dohmen H, Stein M, Reinhardt A, Suwala AK, Wefers AK, Baumgarten P, Ricklefs F, Rushing EJ, Bewerunge-Hudler M, Ketter R, Schittenhelm J, Jaunmuktane Z, Leu S, Greenway FEA, Bridges LR, Jones T, Grady C, Serrano J, Golfinos J, Sen C, Mawrin C, Jungk C, Hänggi D, Westphal M, Lamszus K, Etminan N, Jungwirth G, Herold-Mende C, Unterberg A, Harter PN, Wirsching HG, Neidert MC, Ratliff M, Platten M, Snuderl M, Aldape KD, Brandner S, Hench J, Frank S, Pfister SM, Jones DTW, Reifenberger G, Acker T, Wick W, Weller M, Preusser M, von Deimling A, Sahm F; German Consortium on Aggressive Meningiomas (KAM). Maas SLN, et al. Among authors: wirsching hg. J Clin Oncol. 2021 Dec 1;39(34):3839-3852. doi: 10.1200/JCO.21.00784. Epub 2021 Oct 7. J Clin Oncol. 2021. PMID: 34618539 Free PMC article.
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M, Tabatabai G, Kästner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, Bähr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkhah G, Meixensberger J, Vajkoczy P, Kollias S, Hüsing J, Reifenberger G, Wick W; DIRECTOR Study Group. Weller M, et al. Among authors: wirsching hg. Clin Cancer Res. 2015 May 1;21(9):2057-64. doi: 10.1158/1078-0432.CCR-14-2737. Epub 2015 Feb 5. Clin Cancer Res. 2015. PMID: 25655102 Free article. Clinical Trial.
The management of lomustine overdose in malignant glioma patients.
Wirsching HG, Tritschler I, Palla A, Renner C, Weller M, Tabatabai G. Wirsching HG, et al. Neurooncol Pract. 2014 Dec;1(4):178-183. doi: 10.1093/nop/npu023. Epub 2014 Sep 12. Neurooncol Pract. 2014. PMID: 26034630 Free PMC article.
Predicting outcome of epilepsy after meningioma resection.
Wirsching HG, Morel C, Gmür C, Neidert MC, Baumann CR, Valavanis A, Rushing EJ, Krayenbühl N, Weller M. Wirsching HG, et al. Neuro Oncol. 2016 Jul;18(7):1002-10. doi: 10.1093/neuonc/nov303. Epub 2015 Dec 18. Neuro Oncol. 2016. PMID: 26683139 Free PMC article.
Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial.
Suchorska B, Weller M, Tabatabai G, Senft C, Hau P, Sabel MC, Herrlinger U, Ketter R, Schlegel U, Marosi C, Reifenberger G, Wick W, Tonn JC, Wirsching HG. Suchorska B, et al. Among authors: wirsching hg. Neuro Oncol. 2016 Apr;18(4):549-56. doi: 10.1093/neuonc/nov326. Epub 2016 Jan 27. Neuro Oncol. 2016. PMID: 26823503 Free PMC article. Clinical Trial.
Glioblastoma.
Wirsching HG, Galanis E, Weller M. Wirsching HG, et al. Handb Clin Neurol. 2016;134:381-97. doi: 10.1016/B978-0-12-802997-8.00023-2. Handb Clin Neurol. 2016. PMID: 26948367 Review.
50 results